Acquisition of Patent on a probiotic microbial agent for preventing or improving the loss of alveolar bone

 

OraTicx oral probiotics acquired a Patent on a probiotic microbial agent for preventing or improving the loss of alveolar bone has been registered at the Korean Intellectual Property Office on the 4th of October, 2022. 

 

The present invention relates to a probiotic microbial probiotic preparation for preventing or improving alveolar bone loss.

 

Oral Probiotic oraCMU (Weissella cibaria CMU) is included in a vegetable oil substrate in an amount of 108 to 1010 CFU (colony forming unit) per gram to be prepared as a concentrate, and microbial probiotics for preventing or improving alveolar bone loss act locally in inflammatory tissues.
In addition, it has the effect of suppressing alveolar bone loss by reducing the total number of bacteria.

 

In particular, since living lactobacillus is used as oral care probiotics (OCPs), it is possible to control harmful bacteria that live in blind spots where toothbrushes or gargle fluids do not reach while settling in the oral cavity when ingested. The microbial probiotic formulation of this invention is a nature-friendly next-generation oral care solution that has no side effects that can selectively control harmful bacteria and restore the balance of collapsed microbiome in the oral cavity to fundamentally prevent and improve periodontal disease.

 

 

Patent Number: 10-2451860

Patentee: Orapharm, Inc